BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Däbritz J, Langhorst J, Lügering A, Heidemann J, Mohr M, Wittkowski H, Krummenerl T, Foell D. Improving Relapse Prediction in Inflammatory Bowel Disease by Neutrophil-Derived S100A12: . Inflammatory Bowel Diseases 2013;19:1130-8. [DOI: 10.1097/mib.0b013e318280b1cd] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 Kessel C, Lavric M, Weinhage T, Brueckner M, de Roock S, Däbritz J, Weber J, Vastert SJ, Foell D. Serum biomarkers confirming stable remission in inflammatory bowel disease. Sci Rep 2021;11:6690. [PMID: 33758351 DOI: 10.1038/s41598-021-86251-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lin ST. Role of serum S100A12 in diagnosis and evaluation of ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2016; 24(7): 1103-1106 [DOI: 10.11569/wcjd.v24.i7.1103] [Reference Citation Analysis]
3 Guo X, Huang C, Xu J, Xu H, Liu L, Zhao H, Wang J, Huang W, Peng W, Chen Y, Nie Y, Zhou Y, Zhou Y. Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease. Front Nutr 2022;8:818902. [DOI: 10.3389/fnut.2021.818902] [Reference Citation Analysis]
4 Ge C, Lu Y, Shen H, Zhu L. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis. Scand J Gastroenterol 2022;:1-12. [PMID: 34994661 DOI: 10.1080/00365521.2021.2022193] [Reference Citation Analysis]
5 Wu T, Shi Y, Zhang Y, Zhang M, Zhang L, Ma Z, Zhao D, Wang L, Yu H, Hou Y, Gong J. Lactobacillus rhamnosus LB1 Alleviates Enterotoxigenic Escherichia coli-Induced Adverse Effects in Piglets by Improving Host Immune Response and Anti-Oxidation Stress and Restoring Intestinal Integrity. Front Cell Infect Microbiol 2021;11:724401. [PMID: 34796123 DOI: 10.3389/fcimb.2021.724401] [Reference Citation Analysis]
6 Carvalho A, Lu J, Francis JD, Moore RE, Haley KP, Doster RS, Townsend SD, Johnson JG, Damo SM, Gaddy JA. S100A12 in Digestive Diseases and Health: A Scoping Review. Gastroenterol Res Pract 2020;2020:2868373. [PMID: 32184815 DOI: 10.1155/2020/2868373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
7 Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017;23:894-902. [PMID: 28511198 DOI: 10.1097/mib.0000000000001082] [Cited by in Crossref: 64] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
8 Abdehagh M, Azimirad M, Houri H, Nadalian B, Azimirad F, Olfatifar M, Nasir Shoeibi OK, Yadegar A, Shahrokh S, Mahdavi Roshan M, Asadzadeh Aghdaei H, Zali MR. Serum procalcitonin levels associate with Clostridioides difficile infection in patients with inflammatory bowel disease. BMC Infect Dis 2021;21:1103. [PMID: 34702217 DOI: 10.1186/s12879-021-06804-2] [Reference Citation Analysis]
9 Meng LL, Wu ZJ. Clinical utility of fecal neutrophil-derived biomarkers in evaluating activity of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2014; 22(35): 5473-5479 [DOI: 10.11569/wcjd.v22.i35.5473] [Reference Citation Analysis]
10 Huang X, Zeng Y, Xing X, Zeng J, Gao Y, Cai Z, Xu B, Liu X, Huang A, Liu J. Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection. Proteome Sci 2014;12:22. [PMID: 24839399 DOI: 10.1186/1477-5956-12-22] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
11 Lu C, Liu J, Yao M, Li L, Li G. Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells. BMC Cancer 2020;20:261. [PMID: 32228516 DOI: 10.1186/s12885-020-06768-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Holzinger D, Föll D. [Biomarkers for chronic inflammatory diseases]. Z Rheumatol 2015;74:887-96; quiz 897. [PMID: 26608264 DOI: 10.1007/s00393-015-0009-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Day AS, Adamji M. Commentary: Impact of Fecal Calprotectin Measurement on Decision-Making in Children with Inflammatory Bowel Disease. Front Pediatr 2017;5:133. [PMID: 28634577 DOI: 10.3389/fped.2017.00133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
14 Boyapati RK, Rossi AG, Satsangi J, Ho GT. Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol. 2016;9:567-582. [PMID: 26931062 DOI: 10.1038/mi.2016.14] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 10.2] [Reference Citation Analysis]
15 Westerink F, Huibregtse I, De Hoog M, Bruin S, Meesters E, Brandjes D, Gerdes V. Faecal Inflammatory Biomarkers and Gastrointestinal Symptoms after Bariatric Surgery: A Longitudinal Study. Inflamm Intest Dis 2021;6:109-16. [PMID: 34124182 DOI: 10.1159/000514576] [Reference Citation Analysis]
16 Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World J Gastroenterol 2016; 22(3): 1017-1033 [PMID: 26811644 DOI: 10.3748/wjg.v22.i3.1017] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 46] [Article Influence: 8.8] [Reference Citation Analysis]
17 Mizoguchi E, Subramaniam R, Okada T, Mizoguchi A. A Review of Selected IBD Biomarkers: From Animal Models to Bedside. Diagnostics (Basel) 2021;11:207. [PMID: 33573291 DOI: 10.3390/diagnostics11020207] [Reference Citation Analysis]
18 Hanifeh M, Sankari S, Rajamäki MM, Syrjä P, Kilpinen S, Suchodolski JS, Heilmann RM, Guadiano P, Lidbury J, Steiner JM, Spillmann T. S100A12 concentrations and myeloperoxidase activities are increased in the intestinal mucosa of dogs with chronic enteropathies. BMC Vet Res 2018;14:125. [PMID: 29618371 DOI: 10.1186/s12917-018-1441-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
19 Hanifeh M, Heilmann RM, Sankari S, Rajamäki MM, Mäkitalo L, Syrjä P, Kilpinen S, Suchodolski JS, Steiner JM, Spillmann T. S100A12 concentrations and myeloperoxidase activity in the intestinal mucosa of healthy dogs. BMC Vet Res 2015;11:234. [PMID: 26370713 DOI: 10.1186/s12917-015-0551-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
20 Galgut BJ, Lemberg DA, Day AS, Leach ST. The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases. Front Pediatr 2017;5:292. [PMID: 29404311 DOI: 10.3389/fped.2017.00292] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Nanini HF, Bernardazzi C, Castro F, de Souza HSP. Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets. World J Gastroenterol 2018; 24(41): 4622-4634 [PMID: 30416310 DOI: 10.3748/wjg.v24.i41.4622] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
22 Siddiqui I, Majid H, Abid S. Update on clinical and research application of fecal biomarkers for gastrointestinal diseases. World J Gastrointest Pharmacol Ther 2017; 8(1): 39-46 [PMID: 28217373 DOI: 10.4292/wjgpt.v8.i1.39] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
23 Li Y, Khamou M, Schaarschmidt BM, Umutlu L, Forsting M, Demircioglu A, Haubold J, Koch AK, Bruckmann NM, Sawicki LM, Herrmann K, Boone JH, Langhorst J. Comparison of 18F-FDG PET-MR and fecal biomarkers in the assessment of disease activity in patients with ulcerative colitis. Br J Radiol 2020;93:20200167. [PMID: 32579403 DOI: 10.1259/bjr.20200167] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Zhang Y, Wang PX, Zhang HJ. Role of biomarkers in diagnosis and evaluation of disease activity of Crohn's disease. Shijie Huaren Xiaohua Zazhi 2016; 24(32): 4389-4395 [DOI: 10.11569/wcjd.v24.i32.4389] [Reference Citation Analysis]
25 Liu F, Lee SA, Riordan SM, Zhang L, Zhu L. Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:580803. [PMID: 33392214 DOI: 10.3389/fmed.2020.580803] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Wędrychowicz A, Tomasik P, Zając A, Fyderek K. Prognostic value of assessment of stool and serum IL-1β, IL-1ra and IL-6 concentrations in children with active and inactive ulcerative colitis. Arch Med Sci 2018;14:107-14. [PMID: 29379540 DOI: 10.5114/aoms.2017.68696] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zhang C, Yao R, Chen J, Zou Q, Zeng L. S100 family members: potential therapeutic target in patients with hepatocellular carcinoma: A STROBE study. Medicine (Baltimore) 2021;100:e24135. [PMID: 33546025 DOI: 10.1097/MD.0000000000024135] [Reference Citation Analysis]
28 Derkacz A, Olczyk P, Komosinska-Vassev K. Diagnostic Markers for Nonspecific Inflammatory Bowel Diseases. Dis Markers. 2018;2018:7451946. [PMID: 29991970 DOI: 10.1155/2018/7451946] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
29 Ramos SC, Jeong CD, Mamuad LL, Kim SH, Kang SH, Kim ET, Cho YI, Lee SS, Lee SS. Diet Transition from High-Forage to High-Concentrate Alters Rumen Bacterial Community Composition, Epithelial Transcriptomes and Ruminal Fermentation Parameters in Dairy Cows. Animals (Basel) 2021;11:838. [PMID: 33809588 DOI: 10.3390/ani11030838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
30 Musci JO, Cornish JS, Däbritz J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol 2016;51:531-47. [PMID: 26975751 DOI: 10.1007/s00535-016-1191-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
31 Andersson E, Bergemalm D, Kruse R, Neumann G, D'Amato M, Repsilber D, Halfvarson J. Subphenotypes of inflammatory bowel disease are characterized by specific serum protein profiles. PLoS One 2017;12:e0186142. [PMID: 28982144 DOI: 10.1371/journal.pone.0186142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
32 Däbritz J, Musci J, Foell D. Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World J Gastroenterol 2014; 20(2): 363-375 [PMID: 24574706 DOI: 10.3748/wjg.v20.i2.363] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
33 Ciccocioppo R, Imbesi V, Betti E, Boccaccio V, Kruzliak P, Gallia A, Cangemi GC, Maffe GC, Vanoli A, Merante S, De Amici M, Falcone C, Klersy C, Corazza GR. The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn's Disease: A Cross-Sectional Study. Dig Dis Sci 2015;60:2327-37. [PMID: 25757448 DOI: 10.1007/s10620-015-3619-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]